Rigel Pharmaceuticals (RIGL) PT Raised to $10 at BMO Capital Following Q1 Earnings Beat
Tweet Send to a Friend
BMO Capital raised its price target on Rigel Pharmaceuticals (NASDAQ: RIGL) to $10.00 (from $8.00) while maintaining a Outperform rating.Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
